Person:
YASİN, AYŞE İREM

Loading...
Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
Organizational Unit
Job Title
First Name
AYŞE İREM
Last Name
YASİN
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 17
  • PublicationMetadata only
    The Effect of Intratumoral Budding and Other Histological Features in Predicting Treatment Response in Breast Cancer Patients Receiving Neoadjuvant Therapy
    (2022-11-01) Ozturk C.; DUMAN ÖZTÜRK S.; OKCU O.; Sen B.; YASİN A. İ.; BEDİR R.; YASİN, AYŞE İREM
    Introduction: Neoadjuvant chemotherapy (NAC) is used with increasing frequency in breast cancers. Various clinicopathological parameters predict treatment response (TR). Tumor budding (TB), which is a prognostic parameter in many cancers, can be considered the first stage of the metastatic process. In our study, the relationship between TR and clinicopathological parameters and TB in core biopsy samples of patients before NAC was investigated.
  • PublicationMetadata only
    Bezmialem Vakıf Üniversitesi Tıp Fakültesi Hastanesi Transfüzyon Merkezinde 2012-2013 yılları arasında bağışçı kanlarındaki kan grupları dağılımı
    (2013-11-27T00:00:00Z) Yüksel Salduz, Zeyneb İrem; Çetin, Güven; Özkan Tekin, Tuba; Yasin, Ayşe İrem; Yüce, Seda; Çınar, Ahmet; ÇETİN, GÜVEN; YASİN, AYŞE İREM
  • PublicationMetadata only
    Is There a Relation Between Pretreatment CONUT Score and Neoadjuvant Chemotherapy Response in Breast Cancer Patients?
    (2022-06-01T00:00:00Z) YASİN, Ayşe İrem; TOPÇU, Atakan; YASİN, AYŞE İREM; TOPÇU, ATAKAN
    Objective: To evaluate the relationship between pre-treatment nutritional status and pathological complete response (pCR) rates in patients with breast cancer.
  • PublicationMetadata only
    Impact of Malnutrition on Prognosis in Patients with HER2-negative Metastatic Gastric Cancer
    (2022-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; TOPÇU, ATAKAN; YASİN, AYŞE İREM
    Objective: Malnutrition is common in patients with gastric cancer and may adversely affect their prognosis. This study investigated the impact of malnutrition on overall survival (OS) in patients with metastatic gastric cancer by computing the Malnutrition Universal Screening Tool (MUST), one of the most used nutritional screening tools.
  • PublicationOpen Access
    Anxiety levels of breast cancer patients in Turkey during the COVID-19 pandemic
    (2021-07-01T00:00:00Z) YASİN, Ayşe İrem; TOPÇU, Atakan; SHBAIR, ABDALLAH T.M.; SUCUOĞLU İŞLEYEN, ZEHRA; ÖZTÜRK, AHMET; BEŞİROĞLU, MEHMET; TÜRK, HACI MEHMET; YASİN, AYŞE İREM; TOPÇU, ATAKAN; SHBAIR, ABDALLAH T.M.; SUCUOĞLU İŞLEYEN, ZEHRA; ÖZTÜRK, AHMET; BEŞİROĞLU, MEHMET; TÜRK, HACI MEHMET
    Aim: To assess the anxiety levels of breast cancer patients during the COVID-19 pandemic. Materials & methods: A total of 298 patients completed the State-Trait Anxiety Inventory (STAI-S and STAI-T) and the Visual Analogue Scale for Anxiety (VAS) and VAS for Anxiety in COVID-19 (VAS-CoV). Results: 144 patients were in the high anxiety category for STAI-S, and 202 patients were in the high anxiety category for STAI-T. STAI-T score was significantly high in the metastatic group (p = 0.017). VAS-CoV score in the hormonotherapy group was significantly higher than in the no-treatment group (p = 0.023). There was a positive correlation between VAS-CoV and VAS levels (r = 0.708, p < 0.001), VAS-CoV and STAI-S and STAI-T scores (r = 0.402, p < 0.001; r = 0.185, p = 0.001, respectively), and a negative correlation between education years and STAI-T scores (r = -0.172, p = 0.003). Conclusion: The COVID-19 pandemic is related to high anxiety levels in breast cancer patients.
  • PublicationMetadata only
    Kan ve kan bileşenlerinin imha oranları ve nedenleri
    (2013-11-27T00:00:00Z) Yüksel Salduz, Zeyneb İrem; Çetin, Güven; Yasin, Ayşe İrem; Özkan Tekin, Tuba; Yüce, Seda; YÜKSEL SALDUZ, ZEYNEB İREM; ÇETİN, GÜVEN; YASİN, AYŞE İREM
  • PublicationMetadata only
    Uncommon Testicular Germ Cell Tumor Thrombus in Azygos Vein Detected by FDG PET/CT
    (2021-07-01T00:00:00Z) PEKER, ABDUSSELİM ADİL; TOPRAK, HÜSEYİN; YASİN, Ayşe İrem; AYDIN, MEHMET; PEKER, ABDUSSELİM ADİL; TOPRAK, HÜSEYİN; YASİN, AYŞE İREM; AYDIN, MEHMET
    A 40-year old man admitted to the nuclear medicine department to undergo PET/CT for restaging of known testicular germ cell tumor. The patient had a history of orchiectomy for left testis and left nephrectomy with retroperitoneal lymph node dissection. Histopathology revealed testicular germ cell tumor. During the follow-up period, there is a rapidly expanding mass in posterior mediastinum. PET reveals increased FDG activity in the azygos vein. Contrast-enhanced CT of the thorax showed distended azygos vein with heterogeneously enhancing thrombus and peripheral fat stranding. Findings are consistent with azygos vein tumor thrombosis related to testicular germ cell tumor.
  • PublicationMetadata only
    Tumor-infiltrating lymphocytes (TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy
    (2022-06-01T00:00:00Z) Okcu, Oguzhan; Ozturk, Seda Duman; Ozturk, Cigdem; Sen, Bayram; YASİN, Ayşe İrem; YASİN, AYŞE İREM
    Background and objective: The use of the tumor microenvironment as a target in creating treatment modalities and as a biomarker in predicting treatment response has become increasingly important. Tumor-infiltrating lym-phocytes (TILs), located in the tumor microenvironment, are the fundamental elements of the specific immu-nological response against tumor cells and have prognostic importance in many types of cancer.& nbsp;Materials and methods: Between January 2010 and June 2021, 350 patients who were operated on in our hospital and met the study criteria were included in the study. TILs and tumor-infiltrating lymphocyte volume (TILV) were evaluated in hematoxylin-eosin sections of the patients.& nbsp;Results: Presence of high stromal TILs was associated with improved survival (p = 0.036), distant metastasis (p = 0.009), high nuclear and histological grade (p < 0.001), estrogen receptor (ER) and progesterone receptor (PR) negativity (p < 0.001), high Ki-67 proliferation index (< 0.001), HER2 expression (p = 0.026) level, perineural invasion (p = 0.048), adjuvant chemotherapy (p = 0.005) and radiotherapy (p = 0.055) treatment. High TILV was associated with high nuclear and histological grade (p < 0.001), ER and PR negativity (p < 0.001), HER2 positivity (p = 0.013), high Ki-67 proliferation index (p = 0.001) and high tumor size (p = 0.0011). There was no significant relationship between survival (p = 0.343), distant metastasis (p = 0.632), lymph node metastasis (p = 0.141) and sTIL volume.& nbsp;Conclusion: TILs are an indicator of an anti-tumor immune response, and tumor suppressor efficiency is increased by chemotherapy and immunotherapy treatments. It is one of the factors that determine the success of the treatment. The tumor-infiltrating lymphocyte is an important parameter that can help determine the patient groups to be treated with chemotherapy, prevent unnecessary complications, and be quickly evaluated in all laboratories without any expense.
  • PublicationOpen Access
    Effects of Weight Loss with Bariatric Surgery on Platelet Count and Volume
    (2018-07-01) Ilhan, Muzaffer; KARAMAN, ÖZCAN; Yasin, Ayse Irem; TURGUT, SEDA; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; YASİN, AYŞE İREM; TURGUT, SEDA; TAŞAN, ERTUĞRUL
    Objective: Obesity is a chronic metabolic disorder that leads to the increased risk of cardiovascular diseases. This study aims to investigate the effect of weight loss on the platelet count and volume, which is associated with cardiovascular diseases. Methods: In total, 56 obese patients were recruited for the study. The parameters were retrospectively evaluated before and after 6 months of surgery. Results: The mean weight of the patients was 126.2±23.1 kg before surgery and 91.8±20.5 kg after surgery (p<0.001). The mean platelet counts were 292.5±58.6×10³/µL before surgery and 246.8±59.1×10³/µL after surgery (p<0.001). The mean platelet volumes were 10.4±1.0 fL and 11.6±0.9 fL before and after surgery, respectively (p<0.001). The mean platelet counts before surgery were correlated with the mean platelet volume, mean weight, and mean body mass index (p<0.01, r=−0.39, p<0.01, r=0.35, p<0.01, r=0.41, respectively). The mean platelet counts after surgery were correlated with the mean platelet volume (p<0.001, r=−0.68). Conclusion: This study demonstrated decreased platelet counts and increased platelet volume at 6 months after surgery in obese patients. Further long-term and prospective studies are warranted to clarify these results and pathopsychological mechanisms involved.
  • PublicationOpen Access
    Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
    (2022-01-01T00:00:00Z) YASİN, Ayşe İrem; Aydin, Sabin Goktas; SÜMBÜL, BİLGE; KORAL, LOKMAN; ŞİMŞEK, MELİH; Geredeli, Caglayan; Ozturk, Akin; Perkin, Perihan; Demirtas, Derya; Erdemoglu, Engin; HACIBEKİROĞLU, İLHAN; Cakir, Emre; Tanrikulu, Eda; Coban, Ezgi; Ozcelik, Melike; Celik, Sinemis; Teker, Fatih; AKSOY, ASUDE; Firat, Sedat T.; Tekin, Omer; Kalkan, Ziya; Turken, Orhan; Oven, Bala B.; Dane, Faysal; Bilici, Ahmet; Isikdogan, Abdurrahman; ŞEKER, Mesut; TÜRK, HACI MEHMET; Gumus, Mahmut; YASİN, AYŞE İREM; SÜMBÜL, BİLGE; ŞİMŞEK, MELİH; ŞEKER, MESUT; TÜRK, HACI MEHMET
    Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients.